Biovica signs agreement with clinical-stage US biotech company
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) with a US-based biotech company focusing on next generation CDK inhibitors.
Under the agreement, Biovica will provide TKa testing services utilizing Biovica’s DiviTum® TKa assay and expertise in interpreting TKa measurement dynamics to support drug development and dosage optimization. The agreement will expand DiviTum TKa’s inclusion into a growing list of clinical trials investigating the potential of next generation CDK inhibitor treatment and therefore further increase the likelihood of establishing TKa as a monitoring companion biomarker.
"We continue to experience strong growing demand for our Pharma Services Business and are pleased to see yet another agreement within our core area CDK inhibitors. The agreement adds to our existing portfolio of 14 master service agreements and is an important step towards developing a Companion Diagnostic (CDx) product," said Anders Rylander, CEO of Biovica.